Oncology · Phase II

Top sponsors

• First People's Hospital 261 programs
• Chinese Academy of 198 programs
• George Institute for 118 programs
• United Therapeutics Europe 112 programs
• Telethon Foundation 91 programs
• Takeda 79 programs
• Regeneron UK 71 programs
• MSD Merck Sharp 63 programs
• Ningbo Cancer Hospital 62 programs
• Anaxis Pharma 57 programs
• AstraZeneca 52 programs
• HOFFMANN-LA ROCHE 50 programs

1. TAK-280-1501

   Takeda

   Unresectable Locally Advanced or Metastatic Cancer

   phase 2 · small molecule · active

   1 trial →

2. TAK-385

   Takeda

   Prostate Cancer

   phase 2 · small molecule · completed

   1 trial →

3. TAK-500

   Takeda

   Pancreatic Cancer

   phase 2 · small molecule · terminated

   1 trial →

4. TAK-505

   Takeda

   Malignant Solid Tumors

   phase 2 · small molecule · active

   1 trial →

5. TAK-676-1002

   Takeda

   Solid Neoplasm

   phase 2 · small molecule · active

   1 trial →

6. TAK-700

   Takeda

   Prostate Cancer

   phase 2 · small molecule · completed

   1 trial →

7. TAK-788

   Takeda

   Non-Small Cell Lung Cancer (NSCLC)

   phase 2 · small molecule · terminated

   1 trial →

8. TAK-788

   Takeda

   Carcinoma, Non-Small-Cell Lung

   phase 2 · small molecule · active

   1 trial →

9. TAK-853

   Takeda

   Ovarian Cancer

   phase 2 · small molecule · active

   1 trial →

10. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 · small molecule · completed

    1 trial →

11. TAK-981

    Takeda

    Neoplasms

    phase 2 · small molecule · terminated

    1 trial →

12. TAK-981

    Takeda

    Lymphoma, Non-Hodgkin

    phase 2 · small molecule · terminated

    1 trial →

13. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 · small molecule · completed

    1 trial →

14. TAK228

    Takeda

    Lymphoma

    phase 2 · small molecule · terminated

    1 trial →

15. TARA-002

    Protara Therapeutics

    Non-muscle Invasive Bladder Cancer

    phase 2 · mab · active

    3 trials →

16. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 · small molecule · active

    1 trial →

17. TAS-120-203

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 · small molecule · active

    1 trial →

18. TAS-120-206

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 · small molecule · active

    1 trial →

19. TAX625

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Breast Cancer

    phase 2 · small molecule · active

    1 trial →

20. TCD17620

    Sanofi-aventis Healthcare Pty Ltd

    Solid tumor

    phase 2 · small molecule · active

    1 trial →

21. TCTLR-101

    Lacuna Pharma Pty Ltd

    Cancer

    phase 2 · small molecule · active

    1 trial →

22. TD001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 · small molecule · active

    1 trial →

23. TEBENTAFUSP

    Fondazione Telethon ETS

    metastatic uveal melanoma HLA A*02:01 positive

    phase 2 · small molecule · active

    1 trial →

24. TED14856

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 · small molecule · active

    1 trial →

25. TEDOPI for NSCLC non-small cell lung cancer

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

26. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 · small molecule · active

    1 trial →

27. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 · small molecule · active

    1 trial →

28. TEMOZOLOMIDE for locally advanced rectal cancer (LARC)

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 · small molecule · active

    1 trial →

29. TEP-64Cu-ATSM-Rectum

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 · other · active

    1 trial →

30. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 · small molecule · terminated

    1 trial →

31. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 · small molecule · terminated

    1 trial →

32. TGRX-326

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

33. THIO-101

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

34. THOR-707

    Sanofi Pasteur

    Malignant Melanoma

    phase 2 · small molecule · terminated

    1 trial →

35. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 · small molecule · active

    1 trial →

36. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 · small molecule · active

    1 trial →

37. TISLELIZUMAB

    Fondazione Telethon ETS

    Hodgkin lymphoma

    phase 2 · small molecule · active

    1 trial →

38. TKM-080301

    Arbutus Biopharma Corp

    Cancer

    phase 2 · small molecule · completed

    1 trial →

39. TKM-080301

    Arbutus Biopharma Corp

    Hepatocellular Carcinoma

    phase 2 · small molecule · completed

    1 trial →

40. TL-895, TL-895

    Lacuna Pharma Pty Ltd

    B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 2 · small molecule · active

    1 trial →

41. TNG260

    Tango Therapeutics

    Non Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

42. TNG348

    Tango Therapeutics

    Breast Cancer

    phase 2 · small molecule · terminated

    1 trial →

43. TNG456

    Tango Therapeutics

    Non Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

44. TNG462

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 · small molecule · active

    1 trial →

45. TNG908

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 · small molecule · terminated

    1 trial →

46. TNG908-C101

    Tango Therapeutics

    "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 · small molecule · active

    1 trial →

47. TNT-OES-2

    Disc Medicine

    oesophageal cancer, oesophagogastric junction cancer

    phase 2 · small molecule · active

    1 trial →

48. TOCILIZUMAB for Mantle Cell Lymphoma

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions